You are here » Home » Companies » Company Overview » Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd.

BSE: 532989 Sector: Health care
NSE: BAFNAPH ISIN Code: INE878I01022
BSE 00:00 | 12 Aug 113.45 3.85
(3.51%)
OPEN

111.00

HIGH

113.95

LOW

108.10

NSE 05:30 | 01 Jan Bafna Pharmaceuticals Ltd
OPEN 111.00
PREVIOUS CLOSE 109.60
VOLUME 905
52-Week high 190.70
52-Week low 103.10
P/E 40.81
Mkt Cap.(Rs cr) 268
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 111.00
CLOSE 109.60
VOLUME 905
52-Week high 190.70
52-Week low 103.10
P/E 40.81
Mkt Cap.(Rs cr) 268
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Bafna Pharmaceuticals Ltd. (BAFNAPH) - Chairman Speech

Company chairman speech

Dear Stakeholders

We hope that you have been safe and healthy through this singular andunprecedented challenge that humanity is facing today. Although the demand forpharmaceutical products has been least disrupted in comparison to other industriesoperational challenges have increased manifold. 2020 and 2021 were an extraordinary andchallenging two years for all of us. Despite - the challenges your Company remainedresilient and focused on our strategic priorities.

The growth is mainly due to the company's rearranging operations andrecovering from the I COVID-19 impact which had earlier led to restrictive containmentmeasures involving social distancing remote working and the closure of commercialactivities that resulted in operational challenges. The growth is mainly due to thecompanies rearranging their operations and recovering from the COVID-19 impact which hadearlier led to restrictive containment measures involving social distancing remoteworking and the closure of commercial activities that resulted in operational challenges

According to Pharmaceuticals global market report 2022 the globalpharmaceuticals market is expected to grow from $1454.66 billion in 2021 to $1587.05billion in 2022 at a compound annual growth rate (CAGR) of 9.1%.

With a legacy of over 27 years and a mission to help improve healthcarewith innovation commitment and trust we have continuously worked on enhancing qualityand value for our customers and stakeholders during 2021-22.

Your Company has shown remarkable agility and resilience throughout theyear in unprecedented circumstances. This includes the commitment of hundreds of ourcolleagues who have continued to work in our manufacturing facilities throughout to ensurethat vital medicines continued to be manufactured so as to reach patients on time.

In 2021-22 our overall revenue grew by 21% to INR 8724.24 Lakhs. Thisperformance was possible due to our commitment to deliver quality products maintainingthe highest levels of compliance manufacturing excellence and improving our supply chainin the past years.

We are well positioned for the future with our focused strategy andongoing investments in facility our manufacturing competence and advanced managementpractices to achieve operational excellence.

Despite multiple disruptions resulting from the COVID-19 pandemic andlockdowns our teams including Manufacturing Operations Supply Chain HR IT andFinance have done a remarkable job of ensuring minimum disturbances by optimizing overallproductivity and efficiency without compromising on safety protocols.

We are very grateful to our Board of Directors for their continuedguidance advice and support.

I thank our esteemed shareholders partners and stakeholders forplacing their continued trust and confidence in us which we will emerge stronger together.

Best Regards

S. Hemalatha

Chairperson & Executive Director

DIN:02714329

.